Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Down 7.0% in August

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw a large drop in short interest in August. As of August 31st, there was short interest totalling 313,000 shares, a drop of 7.0% from the August 15th total of 336,500 shares. Based on an average daily volume of 63,900 shares, the short-interest ratio is currently 4.9 days. Approximately 1.3% of the company’s stock are short sold.

Gyre Therapeutics Price Performance

Shares of GYRE stock opened at $14.04 on Wednesday. The stock’s 50 day simple moving average is $12.91 and its 200 day simple moving average is $13.95. Gyre Therapeutics has a twelve month low of $4.80 and a twelve month high of $30.40.

Gyre Therapeutics (NASDAQ:GYRE) last released its earnings results on Tuesday, August 13th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $25.23 million during the quarter. Analysts anticipate that Gyre Therapeutics will post -0.45 earnings per share for the current fiscal year.

Insider Transactions at Gyre Therapeutics

In related news, Director Nassim Usman sold 3,452 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $12.00, for a total value of $41,424.00. Following the transaction, the director now directly owns 1,636 shares of the company’s stock, valued at approximately $19,632. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.92% of the company’s stock.

Institutional Trading of Gyre Therapeutics

Several institutional investors have recently modified their holdings of GYRE. WINTON GROUP Ltd acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter worth approximately $220,000. Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter worth approximately $218,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics during the 2nd quarter worth approximately $166,000. Finally, Rhumbline Advisers bought a new position in shares of Gyre Therapeutics during the 2nd quarter worth approximately $123,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.